LOGO
LOGO

TOI Hits New High - Revenue Projected To Grow 17% To 22% In 2025, Profitable By 2026

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
fyi 18072025 lt

Shares of The Oncology Institute Inc. (TOI) touched a new 52-week high of $3.76 yesterday, driven by renewed investor confidence and growing market enthusiasm surrounding the company's performance and outlook.

This U.S.-based, community-focused oncology care provider operates 67 clinics across California, Florida, Arizona, Oregon, and Nevada. It offers comprehensive cancer treatment services, including chemotherapy, immunotherapy, oncolytics, and radiation oncology. TOI supports patients through coordinated case management, drug formulary oversight, and fully delegated networks of care providers. It also operates a specialty pharmacy that dispenses oral and self-injectable medications both in-office and by mail. Beyond patient care, TOI plays an active role in advancing clinical research in oncology, hematology, and supportive therapies and devices.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.